Vivek Subbiah: Optimizing anti–body drug conjugates and radiopharmaceuticals for precision therapy

Vivek Subbiah shared a post on LinkedIn:

“Sharing this editorial from 2021: Optimizing anti–body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology”

Read further.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.